<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">J. Dermatol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1346-8138</journal-id><journal-id journal-id-type="publisher-id">JDE</journal-id><journal-title-group><journal-title>The Journal of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0385-2407</issn><issn pub-type="epub">1346-8138</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28635026</article-id><article-id pub-id-type="pmc">5697664</article-id><article-id pub-id-type="doi">10.1111/1346-8138.13927</article-id><article-id pub-id-type="publisher-id">JDE13927</article-id><article-categories><subj-group subj-group-type="overline"><subject>Concise Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Concise Communications</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of ixekizumab treatment in Japanese patients with moderate&#x02010;to&#x02010;severe plaque psoriasis: Subgroup analysis of a placebo&#x02010;controlled, phase 3 study (UNCOVER&#x02010;1)</article-title><alt-title alt-title-type="left-running-head">S. Imafuku <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="jde13927-cr-0001" contrib-type="author"><name><surname>Imafuku</surname><given-names>Shinichi</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8568-4349</contrib-id><xref ref-type="aff" rid="jde13927-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jde13927-cr-0002" contrib-type="author" corresp="yes"><name><surname>Torisu&#x02010;Itakura</surname><given-names>Hitoe</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3200-2882</contrib-id><address><email>itakura_hitoe@lilly.com</email></address><xref ref-type="aff" rid="jde13927-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jde13927-cr-0003" contrib-type="author"><name><surname>Nishikawa</surname><given-names>Atsushi</given-names></name><xref ref-type="aff" rid="jde13927-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jde13927-cr-0004" contrib-type="author"><name><surname>Zhao</surname><given-names>Fangyi</given-names></name><xref ref-type="aff" rid="jde13927-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jde13927-cr-0005" contrib-type="author"><name><surname>Cameron</surname><given-names>Gregory S.</given-names></name><xref ref-type="aff" rid="jde13927-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jde13927-cr-0006" contrib-type="author"><collab collab-type="authors">the Japanese UNCOVER&#x02010;1 Study Group</collab></contrib></contrib-group><aff id="jde13927-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>Fukuoka University</institution>
<named-content content-type="city">Fukuoka</named-content>
</aff><aff id="jde13927-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Lilly Research Laboratories</named-content>
<institution>Eli Lilly Japan K.K.</institution>
<named-content content-type="city">Kobe</named-content>
<named-content content-type="country-part">Hyogo</named-content>
<country country="JP">Japan</country>
</aff><aff id="jde13927-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Lilly Research Laboratories</named-content>
<institution>Eli Lilly and Company</institution>
<named-content content-type="city">Indianapolis</named-content>
<named-content content-type="country-part">IN</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: Hitoe Torisu&#x02010;Itakura, M.D., Ph.D., Biomedicine/Musculoskeletal and Autoimmune Product, Medicines Development Unit Japan, Eli Lilly Japan K.K., 7&#x02010;1&#x02010;5 Isogamidori, Chuo&#x02010;Ku, Kobe 651&#x02010;0086, Japan. Email: <email>itakura_hitoe@lilly.com</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><volume>44</volume><issue>11</issue><issue-id pub-id-type="doi">10.1111/jde.2017.44.issue-11</issue-id><fpage>1285</fpage><lpage>1290</lpage><history><date date-type="received"><day>08</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 Japanese Dermatological Association <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 Eli Lilly Japan KK. <italic>The Journal of Dermatology</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Dermatological Association.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDE-44-1285.pdf"/><abstract id="jde13927-abs-0001"><title>Abstract</title><p>The present study describes a subgroup analysis of 33 Japanese patients participating in <styled-content style="fixed-case">UNCOVER</styled-content>&#x02010;1, an international, placebo&#x02010;controlled, phase 3 study of ixekizumab in patients with moderate&#x02010;to&#x02010;severe psoriasis. Patients were randomized to a placebo (<italic>n</italic> = 13) or ixekizumab 80 mg every 4 (<styled-content style="fixed-case">IXEQ</styled-content>4W, <italic>n</italic> = 12) or 2 (<styled-content style="fixed-case">IXEQ</styled-content>2W, <italic>n</italic> = 8) weeks, from week 0&#x02013;12. At week 12, ixekizumab&#x02010;treated patients with a static Physician Global Assessment score 0 or 1 (<styled-content style="fixed-case">sPGA</styled-content> [0,1]; <italic>n</italic> = 16) were re&#x02010;randomized to a placebo (<italic>n</italic> = 6), ixekizumab 80 mg every 12 (<styled-content style="fixed-case">IXEQ</styled-content>12W, <italic>n</italic> = 5) or 4 (<styled-content style="fixed-case">IXEQ</styled-content>4W, <italic>n</italic> = 5) weeks, from week 12&#x02013;60. At week 12, more ixekizumab&#x02010;treated versus placebo&#x02010;treated patients achieved <styled-content style="fixed-case">sPGA</styled-content> (0,1) (&#x02265;66.7% <italic>vs</italic> 0%), &#x02265;75% improvement in Psoriasis Area and Severity Index (&#x02265;75% <italic>vs</italic> 0%), and <styled-content style="fixed-case">sPGA</styled-content> (0) or 100% improvement in Psoriasis Area and Severity Index (both &#x02265;33.3% <italic>vs</italic> 0%), with improved symptoms and quality of life. At week 60, 100% (<styled-content style="fixed-case">IXEQ</styled-content>4W), 40.0% (<styled-content style="fixed-case">IXEQ</styled-content>12W) and 16.7% (placebo) had maintained <styled-content style="fixed-case">sPGA</styled-content> (0,1). From week 0&#x02013;12, treatment&#x02010;emergent adverse events were 76.9% (placebo), 75.0% (<styled-content style="fixed-case">IXEQ</styled-content>4W) and 87.5% (<styled-content style="fixed-case">IXEQ</styled-content>2W), and from week 12&#x02013;60 were 66.7% (placebo) and 100% (<styled-content style="fixed-case">IXEQ</styled-content>12W, <styled-content style="fixed-case">IXEQ</styled-content>4W). Ixekizumab&#x02010;treated patients had no severe treatment&#x02010;emergent adverse events, and one serious <styled-content style="fixed-case">TEAE</styled-content> (<styled-content style="fixed-case">IXEQ</styled-content>4W); infection was the most frequent treatment&#x02010;emergent adverse event. In conclusion, ixekizumab for 60 weeks was effective and safe for Japanese patients with moderate&#x02010;to&#x02010;severe psoriasis, in line with the overall findings from UNCOVER&#x02010;1.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jde13927-kwd-0001">interleukin&#x02010;17A</kwd><kwd id="jde13927-kwd-0002">ixekizumab</kwd><kwd id="jde13927-kwd-0003">Japan</kwd><kwd id="jde13927-kwd-0004">psoriasis</kwd><kwd id="jde13927-kwd-0005">randomized controlled trial</kwd></kwd-group><funding-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="3"/><page-count count="6"/><word-count count="5443"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jde13927</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.6 mode:remove_FC converted:21.11.2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="jde13927-sec-0001"><title>Introduction</title><p>Psoriasis is a chronic, immune&#x02010;mediated, skin condition characterized by red scaly plaques.<xref rid="jde13927-bib-0001" ref-type="ref">1</xref> In Japan, 4.43% of patients (<italic>n</italic> = 67 448) attending dermatology clinics in 2007&#x02013;2008 had psoriasis,<xref rid="jde13927-bib-0002" ref-type="ref">2</xref> which was estimated to affect 0.34% of the population in 2011.<xref rid="jde13927-bib-0003" ref-type="ref">3</xref> In international phase 3 trials, ixekizumab markedly improved the clinical signs and symptoms of moderate&#x02010;to&#x02010;severe psoriasis.<xref rid="jde13927-bib-0004" ref-type="ref">4</xref>, <xref rid="jde13927-bib-0005" ref-type="ref">5</xref> In a single&#x02010;arm study of ixekizumab in Japanese patients (UNCOVER&#x02010;J), 98.7% with moderate&#x02010;to&#x02010;severe psoriasis achieved &#x02265;75% improvement in the Psoriasis Area and Severity Index (PASI 75) at week 12,<xref rid="jde13927-bib-0006" ref-type="ref">6</xref> which was maintained up to 52 weeks with no unexpected safety signals.<xref rid="jde13927-bib-0007" ref-type="ref">7</xref> Herein, we assess the efficacy and safety of ixekizumab for 60 weeks in Japanese patients participating in UNCOVER&#x02010;1, an ongoing, placebo&#x02010;controlled phase 3 study (NCT01474512; JapicCTI&#x02010;121952).<xref rid="jde13927-bib-0004" ref-type="ref">4</xref>
</p></sec><sec id="jde13927-sec-0002"><title>Methods</title><sec id="jde13927-sec-0003"><title>Study design</title><p>Protocol approval and ethics have been described.<xref rid="jde13927-bib-0004" ref-type="ref">4</xref> Eligible patients (aged &#x02265;18 years) had moderate&#x02010;to&#x02010;severe psoriasis &#x02265;6 months before randomization, were candidates for phototherapy and/or systemic therapy, and had body surface area involvement &#x02265;10%, static Physician's Global Assessment (sPGA) score &#x02265;3, and PASI score &#x02265;12 at screening and baseline.<xref rid="jde13927-bib-0004" ref-type="ref">4</xref>
</p><p>Patients were randomized (1:1:1) to receive a placebo or ixekizumab 80 mg (160 mg at week 0) every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) from week 0&#x02013;12 (induction period). At week 12, ixekizumab&#x02010;treated patients with sPGA (0,1) (responders) were re&#x02010;randomized (1:1:1) to a placebo, ixekizumab 80 mg every 12 weeks (IXEQ12W) or IXEQ4W from week 12&#x02013;60 (maintenance period). Placebo&#x02010;treated responders (sPGA [0,1]) received a placebo until relapse (sPGA [&#x02265;3]), then IXEQ4W, and non&#x02010;responders (sPGA [&#x02265;2]) received IXEQ4W.</p></sec><sec id="jde13927-sec-0004"><title>Outcome measures</title><p>Co&#x02010;primary measures were PASI 75 and sPGA (0,1) at week 12. Secondary measures were sPGA (0), &#x02265;90% and 100% improvement in PASI (PASI 90, PASI 100) at week 12; &#x02265;4&#x02010;point improvement in Itch Numeric Rating Scale,<xref rid="jde13927-bib-0008" ref-type="ref">8</xref> change in Dermatology Life Quality Index,<xref rid="jde13927-bib-0009" ref-type="ref">9</xref> change in Nail Psoriasis Severity Index (NAPSI)<xref rid="jde13927-bib-0010" ref-type="ref">10</xref> from week 0&#x02013;12 and maintenance of sPGA (0,1) from week 12&#x02013;60. Safety measures were treatment&#x02010;emergent adverse events (TEAE), serious adverse events and protocol&#x02010;specified TEAE of special interest.<xref rid="jde13927-bib-0004" ref-type="ref">4</xref>
</p></sec><sec id="jde13927-sec-0005"><title>Statistical analysis</title><p>Statistical methods have been described elsewhere.<xref rid="jde13927-bib-0004" ref-type="ref">4</xref> Efficacy analyses included all randomized patients. Safety analyses included all patients who received at least one study dose. Data were summarized using descriptive statistics (SAS version &#x02265;9.2; SAS Institute, Cary, NC, USA). For week 12&#x02013;60, only data for ixekizumab&#x02010;treated responders re&#x02010;randomized at week 12 are presented; data for placebo&#x02010;treated responders and non&#x02010;responders, and ixekizumab&#x02010;treated non&#x02010;responders are not presented. Missing data for categorical efficacy variables (e.g. treatment discontinuation for any reason, no post&#x02010;baseline observations) were imputed as non&#x02010;responders (i.e. did not meet clinical response criteria).</p></sec></sec><sec id="jde13927-sec-0006"><title>Results</title><sec id="jde13927-sec-0007"><title>Patient characteristics</title><p>At week 0, 33 Japanese patients participating in UNCOVER&#x02010;1 (<italic>n</italic> = 1296) were randomized to a placebo (<italic>n</italic> = 13), IXEQ4W (<italic>n</italic> = 12) or IXEQ2W (<italic>n</italic> = 8). At week 12, 16 responders (IXEQ4W <italic>n</italic> = 8, IXEQ2W <italic>n</italic> = 8) were re&#x02010;randomized to a placebo (<italic>n</italic> = 6), IXEQ12W (<italic>n</italic> = 5) or IXEQ4W (<italic>n</italic> = 5). By week 60, three placebo&#x02010;treated and three IXEQ12W&#x02010;treated patients had relapsed. Eight patients discontinued the study, most commonly because of adverse events (<italic>n</italic> = 5).</p><p>Demographics and disease characteristics were similar among treatment groups (Table <xref rid="jde13927-tbl-0001" ref-type="table-wrap">1</xref>). The mean duration of psoriasis was longer for the IXEQ4W group, and previous non&#x02010;biological + biological therapy was more common in the placebo group.</p><table-wrap id="jde13927-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient demographics and baseline disease characteristics of Japanese patients and all patients with moderate&#x02010;to&#x02010;severe plaque psoriasis participating in UNCOVER&#x02010;1</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Variable</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXEQ4W</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXEQ2W</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 13)</th><th align="center" valign="top" rowspan="1" colspan="1">All<xref ref-type="fn" rid="jde13927-note-0002">&#x02020;</xref> (<italic>n</italic> = 431)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 12)</th><th align="center" valign="top" rowspan="1" colspan="1">All<xref ref-type="fn" rid="jde13927-note-0002">&#x02020;</xref> (<italic>n</italic> = 432)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 8)</th><th align="center" valign="top" rowspan="1" colspan="1">All<xref ref-type="fn" rid="jde13927-note-0002">&#x02020;</xref> (<italic>n</italic> = 433)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years (mean &#x000b1; SD)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">51.4 &#x000b1; 14.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">46.4 &#x000b1; 13.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">44.5 &#x000b1; 10.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">45.6 &#x000b1; 13.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">45.5 &#x000b1; 10.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">45.3 &#x000b1; 12.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">9 (69.2)</td><td align="char" char="(" rowspan="1" colspan="1">303 (70.3)</td><td align="char" char="(" rowspan="1" colspan="1">10 (83.3)</td><td align="char" char="(" rowspan="1" colspan="1">289 (66.9)</td><td align="char" char="(" rowspan="1" colspan="1">8 (100)</td><td align="char" char="(" rowspan="1" colspan="1">291 (67.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg (mean &#x000b1; SD)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65.0 &#x000b1; 14.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">91.8 &#x000b1; 25.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">74.6 &#x000b1; 15.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">92.5 &#x000b1; 23.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">71.7 &#x000b1; 10.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">92.4 &#x000b1; 22.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of psoriasis, years (mean &#x000b1; SD)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.2 &#x000b1; 8.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19.5 &#x000b1; 11.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">18.7 &#x000b1; 7.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19.5 &#x000b1; 11.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.9 &#x000b1; 8.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19.9 &#x000b1; 11.9</td></tr><tr><td align="left" colspan="7" rowspan="1">Previous systemic therapy, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;biological<xref ref-type="fn" rid="jde13927-note-0003">&#x02021;</xref> only</td><td align="char" char="(" rowspan="1" colspan="1">4 (30.8)</td><td align="char" char="(" rowspan="1" colspan="1">118 (27.4)</td><td align="char" char="(" rowspan="1" colspan="1">7 (58.3)</td><td align="char" char="(" rowspan="1" colspan="1">132 (30.6)</td><td align="char" char="(" rowspan="1" colspan="1">5 (62.5)</td><td align="char" char="(" rowspan="1" colspan="1">152 (35.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Biological only</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">57 (13.2)</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">62 (14.4)</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">49 (11.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;biological<xref ref-type="fn" rid="jde13927-note-0003">&#x02021;</xref> + biological</td><td align="char" char="(" rowspan="1" colspan="1">5 (38.5)</td><td align="char" char="(" rowspan="1" colspan="1">124 (28.8)</td><td align="char" char="(" rowspan="1" colspan="1">2 (16.7)</td><td align="char" char="(" rowspan="1" colspan="1">106 (24.5)</td><td align="char" char="(" rowspan="1" colspan="1">1 (12.5)</td><td align="char" char="(" rowspan="1" colspan="1">124 (28.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Never used</td><td align="char" char="(" rowspan="1" colspan="1">4 (30.8)</td><td align="char" char="(" rowspan="1" colspan="1">132 (30.6)</td><td align="char" char="(" rowspan="1" colspan="1">3 (25.0)</td><td align="char" char="(" rowspan="1" colspan="1">132 (30.6)</td><td align="char" char="(" rowspan="1" colspan="1">2 (25.0)</td><td align="char" char="(" rowspan="1" colspan="1">108 (24.9)</td></tr><tr><td align="left" colspan="7" rowspan="1">sPGA, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3 (Moderate)</td><td align="char" char="(" rowspan="1" colspan="1">6 (46.2)</td><td align="char" char="(" rowspan="1" colspan="1">204 (47.3)</td><td align="char" char="(" rowspan="1" colspan="1">5 (41.7)</td><td align="char" char="(" rowspan="1" colspan="1">197 (45.6)</td><td align="char" char="(" rowspan="1" colspan="1">4 (50.0)</td><td align="char" char="(" rowspan="1" colspan="1">231 (53.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4 (Severe)</td><td align="char" char="(" rowspan="1" colspan="1">5 (38.5)</td><td align="char" char="(" rowspan="1" colspan="1">193 (44.8)</td><td align="char" char="(" rowspan="1" colspan="1">7 (58.3)</td><td align="char" char="(" rowspan="1" colspan="1">205 (47.5)</td><td align="char" char="(" rowspan="1" colspan="1">3 (37.5)</td><td align="char" char="(" rowspan="1" colspan="1">179 (41.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">5 (Very severe)</td><td align="char" char="(" rowspan="1" colspan="1">2 (15.4)</td><td align="char" char="(" rowspan="1" colspan="1">34 (7.9)</td><td align="char" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">30 (6.9)</td><td align="char" char="(" rowspan="1" colspan="1">1 (12.5)</td><td align="char" char="(" rowspan="1" colspan="1">23 (5.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PASI (mean &#x000b1; SD)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.8 &#x000b1; 12.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">20.3 &#x000b1; 8.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">22.3 &#x000b1; 9.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">20.0 &#x000b1; 7.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">27.6 &#x000b1; 14.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">20.1 &#x000b1; 8.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Itch NRS (mean &#x000b1; SD)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.2 &#x000b1; 3.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.0 &#x000b1; 2.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.0 &#x000b1; 2.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.0 &#x000b1; 2.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.4 &#x000b1; 2.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.2 &#x000b1; 2.4</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">DLQI (mean &#x000b1; SD)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12.9 &#x000b1; 7.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12.8 &#x000b1; 7.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.5 &#x000b1; 7.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.2 &#x000b1; 7.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.9 &#x000b1; 8.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.4 &#x000b1; 7.0</td></tr><tr><td align="left" colspan="7" rowspan="1">NAPSI (if nail psoriasis present)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Patients, <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">10 (76.9)</td><td align="char" char="(" rowspan="1" colspan="1">283 (65.7)</td><td align="char" char="(" rowspan="1" colspan="1">9 (75.0)</td><td align="char" char="(" rowspan="1" colspan="1">283 (65.5)</td><td align="char" char="(" rowspan="1" colspan="1">7 (87.5)</td><td align="char" char="(" rowspan="1" colspan="1">284 (65.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">36.8 &#x000b1; 28.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26.1 &#x000b1; 20.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.9 &#x000b1; 9.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.1 &#x000b1; 18.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.6 &#x000b1; 11.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.6 &#x000b1; 18.9</td></tr><tr><td align="left" colspan="7" rowspan="1">PSSI (if scalp psoriasis present)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Patients, <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">13 (100)</td><td align="char" char="(" rowspan="1" colspan="1">393 (91.2)</td><td align="char" char="(" rowspan="1" colspan="1">12 (100)</td><td align="char" char="(" rowspan="1" colspan="1">413 (95.6)</td><td align="char" char="(" rowspan="1" colspan="1">8 (100)</td><td align="char" char="(" rowspan="1" colspan="1">393 (90.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">34.2 &#x000b1; 16.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">21.8 &#x000b1; 15.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.8 &#x000b1; 17.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19.9 &#x000b1; 14.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">30.1 &#x000b1; 15.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">21.1 &#x000b1; 14.7</td></tr></tbody></table><table-wrap-foot><fn id="jde13927-note-0001"><p>DLQI, Dermatology Life Quality Index; IXEQ2W, ixekizumab 80 mg once every 2 weeks; IXEQ4W, ixekizumab 80 mg once every 4 weeks; JPN, Japanese; NAPSI, Nail Psoriasis Severity Index; NRS, Numeric Rating Scale; PSSI, Psoriasis Scalp Severity Index; SD, standard deviation; sPGA, static Physician Global Assessment.</p></fn><fn id="jde13927-note-0002"><p>
<sup>&#x02020;</sup>Patient demographic (age, sex, weight) and baseline disease characteristics (duration of psoriasis, Psoriasis Area and Severity Index [PASI] score, previous therapy) for the overall UNCOVER&#x02010;1 population have been reported previously.<xref rid="jde13927-bib-0004" ref-type="ref">4</xref>
</p></fn><fn id="jde13927-note-0003"><p>
<sup>&#x02021;</sup>Previous non&#x02010;biological therapies were methotrexate, cyclosporine, retinoids and psoralen plus ultraviolet light of A (long) wavelength.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jde13927-sec-0008"><title>Efficacy</title><p>At week 12, eight (100%) IXEQ2W&#x02010;treated and eight (66.7%) IXEQ4W&#x02010;treated patients achieved sPGA (0,1), and eight (100%) IXEQ2W&#x02010;treated and nine (75.0%) IXEQ4W&#x02010;treated patients achieved PASI 75 (Table <xref rid="jde13927-tbl-0002" ref-type="table-wrap">2</xref>). No placebo&#x02010;treated patient achieved sPGA (0,1) or PASI 75, nor sPGA (0), PASI 90 or PASI 100. Furthermore, six (75.0%) IXEQ2W&#x02010;treated patients and seven (58.3%) IXEQ4W&#x02010;treated patients achieved PASI 90, with at least three (37.5%) IXEQ2W&#x02010;treated and four (33.3%) IXEQ4W&#x02010;treated patients achieving complete resolution of psoriasis plaques (sPGA [0] or PASI 100).</p><table-wrap id="jde13927-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Efficacy outcomes of ixekizumab treatment in Japanese patients and all patients with moderate&#x02010;to&#x02010;severe plaque psoriasis participating in UNCOVER&#x02010;1</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1">Variable</th><th align="center" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Induction period (week 0&#x02013;12)</th><th align="center" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Maintenance period (week 12&#x02013;60)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXEQ4W</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXEQ2W</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXE &#x02192; placebo</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXE &#x02192; IXEQ12W</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXE &#x02192; IXEQ4W</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 13)</th><th align="center" valign="top" rowspan="1" colspan="1">All<xref ref-type="fn" rid="jde13927-note-0006">&#x02020;</xref> (<italic>n</italic> = 431)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 12)</th><th align="center" valign="top" rowspan="1" colspan="1">All<xref ref-type="fn" rid="jde13927-note-0006">&#x02020;</xref> (<italic>n</italic> = 432)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 8)</th><th align="center" valign="top" rowspan="1" colspan="1">All<xref ref-type="fn" rid="jde13927-note-0006">&#x02020;</xref> (<italic>n</italic> = 433)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 6)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 226)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 5)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 227)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 5)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 229)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">sPGA (0,1), <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">14 (3.2)</td><td align="char" char=" " rowspan="1" colspan="1">8 (66.7)</td><td align="char" char=" " rowspan="1" colspan="1">330 (76.4)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">8 (100)</td><td align="char" char=" " rowspan="1" colspan="1">354 (81.8)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">1 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">17 (7.5)</td><td align="char" char=" " rowspan="1" colspan="1">2 (40.0)</td><td align="char" char=" " rowspan="1" colspan="1">85 (37.4)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">5 (100)</td><td align="char" char=" " rowspan="1" colspan="1">167 (72.9)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">sPGA (0), <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">4 (33.3)</td><td align="char" char=" " rowspan="1" colspan="1">149 (34.5)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">5 (62.5)</td><td align="char" char=" " rowspan="1" colspan="1">160 (37.0)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" char=" " rowspan="1" colspan="1">NR</td><td align="char" char=" " rowspan="1" colspan="1">NR</td><td align="char" char=" " rowspan="1" colspan="1">NR</td><td align="char" char=" " rowspan="1" colspan="1">NR</td><td align="char" char=" " rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">PASI 75, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">17 (3.9)</td><td align="char" char=" " rowspan="1" colspan="1">9 (75.0)</td><td align="char" char=" " rowspan="1" colspan="1">357 (82.6)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">8 (100)</td><td align="char" char=" " rowspan="1" colspan="1">386 (89.1)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">1 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">20 (8.8)</td><td align="char" char=" " rowspan="1" colspan="1">2 (40.0)</td><td align="char" char=" " rowspan="1" colspan="1">104 (45.8)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">5 (100)</td><td align="char" char=" " rowspan="1" colspan="1">178 (77.7)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">PASI 90, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.5)</td><td align="char" char=" " rowspan="1" colspan="1">7 (58.3)</td><td align="char" char=" " rowspan="1" colspan="1">279 (64.6)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">6 (75.0)</td><td align="char" char=" " rowspan="1" colspan="1">307 (70.9)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">1 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">10 (4.4)</td><td align="char" char=" " rowspan="1" colspan="1">2 (40.0)</td><td align="char" char=" " rowspan="1" colspan="1">83 (36.6)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">5 (100)</td><td align="char" char=" " rowspan="1" colspan="1">162 (70.7)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">PASI 100, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">4 (33.3)</td><td align="char" char=" " rowspan="1" colspan="1">145 (33.6)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">3 (37.5)</td><td align="char" char=" " rowspan="1" colspan="1">153 (35.3)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">6 (2.7)</td><td align="char" char=" " rowspan="1" colspan="1">2 (40.0)</td><td align="char" char=" " rowspan="1" colspan="1">46 (20.3)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">3 (60.0)</td><td align="char" char=" " rowspan="1" colspan="1">119 (52.0)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td></tr><tr><td align="left" colspan="13" rowspan="1">Itch NRS (change from BL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>n</italic> (with measurement)</td><td align="char" char=" " rowspan="1" colspan="1">10</td><td align="char" char=" " rowspan="1" colspan="1">405</td><td align="char" char=" " rowspan="1" colspan="1">9</td><td align="char" char=" " rowspan="1" colspan="1">406</td><td align="char" char=" " rowspan="1" colspan="1">8</td><td align="char" char=" " rowspan="1" colspan="1">417</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;1.1 (2.81)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.3 (0.12)<xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;5.2 (2.68)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;5.4 (0.12)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>, <xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;6.6 (2.56)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;5.6 (0.12)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>, <xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" colspan="13" rowspan="1">Itch NRS (&#x02265;4&#x02010;point improvement from BL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>n</italic> (BL score &#x02265;4)</td><td align="char" char=" " rowspan="1" colspan="1">11</td><td align="char" char=" " rowspan="1" colspan="1">374</td><td align="char" char=" " rowspan="1" colspan="1">11</td><td align="char" char=" " rowspan="1" colspan="1">379</td><td align="char" char=" " rowspan="1" colspan="1">7</td><td align="char" char=" " rowspan="1" colspan="1">391</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">2 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">58 (15.5)</td><td align="char" char=" " rowspan="1" colspan="1">5 (45.5)</td><td align="char" char=" " rowspan="1" colspan="1">305 (80.5)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">7 (100)</td><td align="char" char=" " rowspan="1" colspan="1">336 (85.9)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>
</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" colspan="13" rowspan="1">DLQI (change from BL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>n</italic> (with measurement)</td><td align="char" char=" " rowspan="1" colspan="1">10</td><td align="char" char=" " rowspan="1" colspan="1">403</td><td align="char" char=" " rowspan="1" colspan="1">9</td><td align="char" char=" " rowspan="1" colspan="1">407</td><td align="char" char=" " rowspan="1" colspan="1">8</td><td align="char" char=" " rowspan="1" colspan="1">414</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;2.6 (8.22)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;1.0 (0.27)<xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;9.0 (6.91)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;10.7 (0.27)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>, <xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;13.3 (7.38)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;11.1 (0.26)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>, <xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" colspan="13" rowspan="1">NAPSI (change from BL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<italic>n</italic> (with measurement)</td><td align="char" char=" " rowspan="1" colspan="1">8</td><td align="char" char=" " rowspan="1" colspan="1">267</td><td align="char" char=" " rowspan="1" colspan="1">7</td><td align="char" char=" " rowspan="1" colspan="1">266</td><td align="char" char=" " rowspan="1" colspan="1">7</td><td align="char" char=" " rowspan="1" colspan="1">275</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;1.0 (12.52)</td><td align="char" char=" " rowspan="1" colspan="1">2.17 (0.67)<xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;1.14 (5.96)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;7.19 (0.66)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>, <xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;11.29 (7.99)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;7.24 (0.66)<xref ref-type="fn" rid="jde13927-note-0005">**</xref>, <xref ref-type="fn" rid="jde13927-note-0007">&#x02021;</xref>
</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td><td align="char" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn id="jde13927-note-0004"><p>BL, baseline; DLQI, Dermatology Life Quality Index; IXE, ixekizumab; IXEQ2W, ixekizumab 80 mg once every 2 weeks; IXEQ4W, ixekizumab 80 mg once every 4 weeks; JPN, Japanese; NAPSI, Nail Psoriasis Severity Index; NR, not reported; NRS, Numeric Rating Scale; SD, standard deviation.</p></fn><fn id="jde13927-note-0005"><p>**<italic>P</italic> &#x0003c; 0.001, *<italic>P</italic> &#x0003c; 0.05 compared with placebo; <italic>P</italic>&#x02010;values are from logistic regression analyses or Fisher's exact test, if the response rate for placebo was 0, of categorical efficacy variables, and mixed model repeated measures (MMRM) analyses of continuous efficacy variables. For categorical efficacy variables, missing data were imputed with non&#x02010;responder imputation (NRI).</p></fn><fn id="jde13927-note-0006"><p>
<sup>&#x02020;</sup>Efficacy outcomes (static Physician Global Assessment [sPGA] [0], [0,1]; Psoriasis Area and Severity Index [PASI 75, PASI 90, PASI 100) for the overall UNCOVER&#x02010;1 population have been reported previously.<xref rid="jde13927-bib-0004" ref-type="ref">4</xref>
</p></fn><fn id="jde13927-note-0007"><p>
<sup>&#x02021;</sup>Values are least square mean (standard error) from MMRM analyses.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Five (all) IXEQ4W&#x02010;treated, two IXEQ12W&#x02010;treated and one placebo&#x02010;treated patient maintained sPGA (0,1) until week 60 (Table <xref rid="jde13927-tbl-0002" ref-type="table-wrap">2</xref>). PASI response rates were numerically greater for IXEQ4W than IXEQ12W and the placebo.</p><p>At week 12, improvements in Itch Numeric Rating Scale and Dermatology Life Quality Index scores were numerically greater for IXEQ2W than IXEQ4W, and were minimal for the placebo (Table <xref rid="jde13927-tbl-0002" ref-type="table-wrap">2</xref>). Improvement in NAPSI scores were minimal for the placebo and IXEQ4W, but more marked for IXEQ2W.</p></sec><sec id="jde13927-sec-0009"><title>Safety</title><p>In the Japanese subgroup, TEAE were reported by 10 placebo&#x02010;treated and 16 ixekizumab&#x02010;treated patients from week 0&#x02013;12, and four placebo&#x02010;treated and 10 (all) ixekizumab&#x02010;treated patients from week 12&#x02013;60; for ixekizumab&#x02010;treated patients, none were considered severe (Table <xref rid="jde13927-tbl-0003" ref-type="table-wrap">3</xref>). TEAE considered possibly drug&#x02010;related were reported by nine (week 0&#x02013;12) and two (week 12&#x02013;60) ixekizumab&#x02010;treated patients. Three IXEQ4W&#x02010;treated patients discontinued because of generalized pruritus (mild severity), allergic edema (moderate severity) and bronchopneumonia (moderate severity, also considered a serious adverse event). No deaths were reported.</p><table-wrap id="jde13927-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Safety overview of ixekizumab treatment in Japanese patients and all patients with moderate&#x02010;to&#x02010;severe plaque psoriasis participating in UNCOVER&#x02010;1</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1">Variable<xref ref-type="fn" rid="jde13927-note-0009">&#x02020;</xref>
</th><th align="left" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Induction period (week 0&#x02013;12)</th><th align="left" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Maintenance period (week 12&#x02013;60)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXEQ4W</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXEQ2W</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXE &#x02192; Placebo</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXE &#x02192; IXEQ12W</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IXE &#x02192; IXEQ4W</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 13)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 431)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 12)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 432)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 8)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 433)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 6)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 226)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 5)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 227)</th><th align="center" valign="top" rowspan="1" colspan="1">JPN (<italic>n</italic> = 5)</th><th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 229)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients with &#x02265;1 TEAE, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">10 (76.9)</td><td align="char" char=" " rowspan="1" colspan="1">210 (48.7)</td><td align="char" char=" " rowspan="1" colspan="1">9 (75.0)</td><td align="char" char=" " rowspan="1" colspan="1">264 (61.1)</td><td align="char" char=" " rowspan="1" colspan="1">7 (87.5)</td><td align="char" char=" " rowspan="1" colspan="1">257 (59.4)</td><td align="char" char=" " rowspan="1" colspan="1">4 (66.7)</td><td align="char" char=" " rowspan="1" colspan="1">123 (54.4)</td><td align="char" char=" " rowspan="1" colspan="1">5 (100)</td><td align="char" char=" " rowspan="1" colspan="1">168 (74.0)</td><td align="char" char=" " rowspan="1" colspan="1">5 (100)</td><td align="char" char=" " rowspan="1" colspan="1">182 (79.5)</td></tr><tr><td align="left" colspan="13" rowspan="1">TEAE by severity, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mild</td><td align="char" char=" " rowspan="1" colspan="1">9 (69.2)</td><td align="char" char=" " rowspan="1" colspan="1">104 (24.1)</td><td align="char" char=" " rowspan="1" colspan="1">7 (58.3)</td><td align="char" char=" " rowspan="1" colspan="1">147 (34.0)</td><td align="char" char=" " rowspan="1" colspan="1">7 (87.5)</td><td align="char" char=" " rowspan="1" colspan="1">164 (37.9)</td><td align="char" char=" " rowspan="1" colspan="1">4 (66.7)</td><td align="char" char=" " rowspan="1" colspan="1">59 (26.1)</td><td align="char" char=" " rowspan="1" colspan="1">2 (40.0)</td><td align="char" char=" " rowspan="1" colspan="1">72 (31.7)</td><td align="char" char=" " rowspan="1" colspan="1">3 (60.0)</td><td align="char" char=" " rowspan="1" colspan="1">78 (34.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Moderate</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">88 (20.4)</td><td align="char" char=" " rowspan="1" colspan="1">2 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">100 (23.1)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">79 (18.2)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">55 (24.3)</td><td align="char" char=" " rowspan="1" colspan="1">3 (60.0)</td><td align="char" char=" " rowspan="1" colspan="1">84 (37.0)</td><td align="char" char=" " rowspan="1" colspan="1">2 (40.0)</td><td align="char" char=" " rowspan="1" colspan="1">85 (37.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Severe</td><td align="char" char=" " rowspan="1" colspan="1">1 (7.7)</td><td align="char" char=" " rowspan="1" colspan="1">18 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">17 (3.9)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">14 (3.2)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">9 (4.0)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">12 (5.3)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">19 (8.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">TEAE possibly related to study drug, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">49 (11.4)</td><td align="char" char=" " rowspan="1" colspan="1">6 (50.0)</td><td align="char" char=" " rowspan="1" colspan="1">111 (25.7)</td><td align="char" char=" " rowspan="1" colspan="1">3 (37.5)</td><td align="char" char=" " rowspan="1" colspan="1">127 (29.3)</td><td align="char" char=" " rowspan="1" colspan="1">1 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">39 (17.3)</td><td align="char" char=" " rowspan="1" colspan="1">1 (20.0)</td><td align="char" char=" " rowspan="1" colspan="1">42 (18.5)</td><td align="char" char=" " rowspan="1" colspan="1">1 (20.0)</td><td align="char" char=" " rowspan="1" colspan="1">71 (31.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Discontinuation because of TEAE, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">1 (7.7)</td><td align="char" char=" " rowspan="1" colspan="1">6 (1.4)</td><td align="char" char=" " rowspan="1" colspan="1">3 (25.0)</td><td align="char" char=" " rowspan="1" colspan="1">10 (2.3)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">10 (2.3)</td><td align="char" char=" " rowspan="1" colspan="1">1 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">4 (1.8)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">9 (3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Death, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">SAE, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">1 (7.7)</td><td align="char" char=" " rowspan="1" colspan="1">5 (1.2)</td><td align="char" char=" " rowspan="1" colspan="1">1 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">12 (2.8)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">6 (1.4)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">7 (3.1)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">9 (4.0)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">15 (6.6)</td></tr><tr><td align="left" colspan="13" rowspan="1">Selected TEAE of special interest, <italic>n</italic> (%)<xref ref-type="fn" rid="jde13927-note-0010">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Infection</td><td align="char" char=" " rowspan="1" colspan="1">3 (23.1)</td><td align="char" char=" " rowspan="1" colspan="1">106 (24.6)</td><td align="char" char=" " rowspan="1" colspan="1">3 (25.0)</td><td align="char" char=" " rowspan="1" colspan="1">128 (29.6)</td><td align="char" char=" " rowspan="1" colspan="1">2 (25.0)</td><td align="char" char=" " rowspan="1" colspan="1">124 (28.6)</td><td align="char" char=" " rowspan="1" colspan="1">2 (33.3)</td><td align="char" char=" " rowspan="1" colspan="1">74 (32.7)</td><td align="char" char=" " rowspan="1" colspan="1">5 (100)</td><td align="char" char=" " rowspan="1" colspan="1">116 (51.1)</td><td align="char" char=" " rowspan="1" colspan="1">3 (60.0)</td><td align="char" char=" " rowspan="1" colspan="1">129 (56.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cytopenias</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">6 (1.4)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">3 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">4 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">1 (20.0)</td><td align="char" char=" " rowspan="1" colspan="1">3 (1.3)</td><td align="char" char=" " rowspan="1" colspan="1">1 (20.0)</td><td align="char" char=" " rowspan="1" colspan="1">7 (3.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Allergic/hypersensitivity reactions</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">10 (2.3)</td><td align="char" char=" " rowspan="1" colspan="1">1 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">19 (4.4)</td><td align="char" char=" " rowspan="1" colspan="1">1 (12.5)</td><td align="char" char=" " rowspan="1" colspan="1">14 (3.2)</td><td align="char" char=" " rowspan="1" colspan="1">1 (16.7)</td><td align="char" char=" " rowspan="1" colspan="1">7 (3.1)</td><td align="char" char=" " rowspan="1" colspan="1">1 (20.0)</td><td align="char" char=" " rowspan="1" colspan="1">10 (4.4)</td><td align="char" char=" " rowspan="1" colspan="1">1 (20.0)</td><td align="char" char=" " rowspan="1" colspan="1">21 (9.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Injection&#x02010;site reactions</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">13 (3.0)</td><td align="char" char=" " rowspan="1" colspan="1">1 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">52 (12.0)</td><td align="char" char=" " rowspan="1" colspan="1">1 (12.5)</td><td align="char" char=" " rowspan="1" colspan="1">69 (15.9)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">12 (5.3)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">16 (7.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Malignancies</td><td align="char" char=" " rowspan="1" colspan="1">1 (7.7)</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.5)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">3 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Abnormal liver function</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">6 (1.4)</td><td align="char" char=" " rowspan="1" colspan="1">1 (8.3)</td><td align="char" char=" " rowspan="1" colspan="1">7 (1.6)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">4 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">4 (1.8)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">5 (2.2)</td><td align="char" char=" " rowspan="1" colspan="1">2 (40.0)</td><td align="char" char=" " rowspan="1" colspan="1">12 (5.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CVD</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">3 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.4)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">3 (1.3)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">3 (1.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">IBD</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.2)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.2)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.4)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="jde13927-note-0008"><p>CVD, cerebrocardiovascular disease; IBD, inflammatory bowel disease; IXE, ixekizumab; IXEQ2W, ixekizumab 80 mg once every 2 weeks; IXEQ4W, ixekizumab 80 mg once every 4 weeks; IXEQ12W, ixekizumab 80 mg once every 12 weeks; JPN, Japanese; SAE, serious adverse event; TEAE, treatment&#x02010;emergent adverse event.</p></fn><fn id="jde13927-note-0009"><p>
<sup>&#x02020;</sup>For all variables, <italic>n</italic> (%) refers to the number (%) of patients.</p></fn><fn id="jde13927-note-0010"><p>
<sup>&#x02021;</sup>Adverse events were coded and summarized using the Medical Dictionary for Regulatory Activities, Version 16.1.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>In ixekizumab&#x02010;treated patients, infection, particularly nasopharyngitis, was the most frequently reported TEAE of special interest (Table <xref rid="jde13927-tbl-0003" ref-type="table-wrap">3</xref>). All infections were mild, except for moderate cases of bronchopneumonia (<italic>n</italic> = 1), nasopharyngitis (<italic>n</italic> = 2), tinea pedis (<italic>n</italic> = 1) and influenza (<italic>n</italic> = 1). Cytopenias (leukopenia and neutropenia [<italic>n</italic> = 1], leukopenia and lymphopenia [<italic>n</italic> = 1]) were mild, all allergic/hypersensitivity reactions were non&#x02010;anaphylactic, and all injection&#x02010;site reactions were mild and resolved within 1&#x02013;3 days. One case of elevated alanine aminotransferase and aspartate aminotransferase concentrations above normal limits during the induction period resulted in study discontinuation at week 44 after re&#x02010;randomization from IXEQ4W to a placebo at week 12, and two cases of mild increases in alanine aminotransferase concentrations resolved during the study. No patients had tuberculosis.</p></sec></sec><sec id="jde13927-sec-0010"><title>Discussion</title><p>Ixekizumab effectively reduced the symptoms and signs of moderate&#x02010;to&#x02010;severe psoriasis in Japanese patients participating in UNCOVER&#x02010;1. At week 12, high levels of psoriasis clearance (sPGA [0,1], PASI 75) were seen in &#x02265;66.7% of ixekizumab&#x02010;treated patients and were maintained through to week 60 (sPGA [0,1]), with IXEQ2W (induction) and IXEQ4W (maintenance) providing the highest response rates. Furthermore, ixekizumab improved nail psoriasis, itch severity and quality of life with an acceptable safety profile.</p><p>Efficacy findings for the 33 Japanese patients were in line with those for the overall UNCOVER&#x02010;1 population.<xref rid="jde13927-bib-0004" ref-type="ref">4</xref> Both populations achieved high levels of psoriasis clearance at week 12; in the overall population, sPGA (0,1) and PASI 75 were significantly (<italic>P</italic> &#x0003c; 0.001) greater for ixekizumab than the placebo, and numerically greater for IXEQ2W than IXEQ4W (Table <xref rid="jde13927-tbl-0002" ref-type="table-wrap">2</xref>).<xref rid="jde13927-bib-0004" ref-type="ref">4</xref> Doses of ixekizumab every 4 weeks provided the best opportunity for maintaining psoriasis clearance (sPGA [0,1]) in both populations (Table <xref rid="jde13927-tbl-0002" ref-type="table-wrap">2</xref>). The low mean baseline NAPSI score of IXEQ4W&#x02010;treated Japanese patients (Table <xref rid="jde13927-tbl-0001" ref-type="table-wrap">1</xref>) might have influenced the difference in mean change in NAPSI scores from week 0&#x02013;12 between Japanese patients and the overall population (Table <xref rid="jde13927-tbl-0002" ref-type="table-wrap">2</xref>). The present findings were also in line with those of UNCOVER&#x02010;J, including high levels of psoriasis clearance (PASI 75, sPGA [0,1]) after 12 weeks of IXEQ2W,<xref rid="jde13927-bib-0006" ref-type="ref">6</xref> which were maintained up to 52 weeks with IXEQ4W,<xref rid="jde13927-bib-0007" ref-type="ref">7</xref> and improved the Dermatology Life Quality Index and Itch Numeric Rating Scale.<xref rid="jde13927-bib-0006" ref-type="ref">6</xref>, <xref rid="jde13927-bib-0007" ref-type="ref">7</xref>
</p><p>Ixekizumab was well tolerated, with no Japanese&#x02010;specific safety findings. A higher proportion of ixekizumab&#x02010;treated Japanese patients reported TEAE than the overall UNCOVER&#x02010;1 population (Table <xref rid="jde13927-tbl-0003" ref-type="table-wrap">3</xref>). However, most TEAE were mild to moderate. In addition, serious adverse event incidence was low; TEAE of special interest incidence was similar to that of the overall population; infection was the most common TEAE of special interest, a finding similar for the overall<xref rid="jde13927-bib-0004" ref-type="ref">4</xref> and UNCOVER&#x02010;J<xref rid="jde13927-bib-0006" ref-type="ref">6</xref>, <xref rid="jde13927-bib-0007" ref-type="ref">7</xref> populations, and other biological therapies tested in Japanese patients;<xref rid="jde13927-bib-0011" ref-type="ref">11</xref>, <xref rid="jde13927-bib-0012" ref-type="ref">12</xref>, <xref rid="jde13927-bib-0013" ref-type="ref">13</xref>, <xref rid="jde13927-bib-0014" ref-type="ref">14</xref> TEAE&#x02010;related study discontinuations were few; no deaths were reported.</p><p>In conclusion, ixekizumab&#x02010;treated Japanese patients with moderate&#x02010;to&#x02010;severe psoriasis attained clinically meaningful reductions in symptoms and severity for up to 60 weeks with an acceptable safety profile. These findings are in line with the overall UNCOVER&#x02010;1<xref rid="jde13927-bib-0004" ref-type="ref">4</xref> and UNCOVER&#x02010;J<xref rid="jde13927-bib-0006" ref-type="ref">6</xref>, <xref rid="jde13927-bib-0007" ref-type="ref">7</xref> populations, further supporting the favorable benefit/risk profile of ixekizumab in Japanese patients.</p></sec><sec id="jde13927-sec-0012"><title>Conflict of Interest</title><p>All authors, except S. I., are employees of and own stock in Eli Lilly and Company. S. I. has received consultancy and speaker fees from Eli Lilly Japan K.K.</p></sec></body><back><ack id="jde13927-sec-0011"><title>Acknowledgments</title><p>The authors thank all UNCOVER&#x02010;1 study participants and the Japanese UNCOVER&#x02010;1 Study Group: Shinichi Imafuku of Fukuoka University Hospital, Kunio Iwahara of Koto Hospital, Mamitaro Ohtsuki of Jichi Medical University Hospital, Norito Kato of University Hospital Kyoto Prefectural University of Medicine, Tadashi Terui of Nihon University Itabashi Hospital, Yoshiki Tokura of Hamamatsu University Hospital, Hideshi Torii of Japan Community Health Care Organization Tokyo Yamate Medical Center, Hideki Nakajima of Kochi Medical School Hospital, Norikazu Fujii of Shiga University of Medical Science Hospital and Akimichi Morita of Nagoya City University Hospital. The authors thank Yoji Morisaki and Ko Nakajo, Eli Lilly Japan K.K.; and Olawale O Osuntokun, Eli Lilly and Company, for their consultation on interpretation of data. This study was sponsored by Eli Lilly and Company, manufacturer of ixekizumab. Medical writing assistance was provided by Julie Monk, PhD, CMPP, and Mark Snape, MB BS, CMPP, of ProScribe &#x02013; Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3). Eli Lilly and Company was involved in the study design, data collection, data analysis, and preparation of the manuscript.</p></ack><ref-list content-type="cited-references" id="jde13927-bibl-0001"><title>References</title><ref id="jde13927-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jde13927-cit-0001">
<string-name>
<surname>Lowes</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Suarez&#x02010;Farinas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Immunology of psoriasis</article-title>. <source>Annu Rev Immunol</source>
<year>2014</year>; <volume>32</volume>: <fpage>227</fpage>&#x02013;<lpage>255</lpage>.<pub-id pub-id-type="pmid">24655295</pub-id></mixed-citation></ref><ref id="jde13927-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jde13927-cit-0002">
<string-name>
<surname>Furue</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yamazaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jimbow</surname>
<given-names>K</given-names>
</string-name>
<italic>et al</italic>
<article-title>Prevalence of dermatological disorders in Japan: a nationwide, cross&#x02010;sectional, seasonal, multicenter, hospital&#x02010;based study</article-title>. <source>J Dermatol</source>
<year>2011</year>; <volume>38</volume>: <fpage>310</fpage>&#x02013;<lpage>320</lpage>.<pub-id pub-id-type="pmid">21426384</pub-id></mixed-citation></ref><ref id="jde13927-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jde13927-cit-0003">
<string-name>
<surname>Kubota</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kamijima</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic>
<article-title>Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database</article-title>. <source>BMJ Open</source>
<year>2015</year>; <volume>5</volume>: <fpage>e006450</fpage>.</mixed-citation></ref><ref id="jde13927-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jde13927-cit-0004">
<string-name>
<surname>Gordon</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Blauvelt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Papp</surname>
<given-names>KA</given-names>
</string-name>
<italic>et al</italic>
<article-title>Phase 3 trials of ixekizumab in moderate&#x02010;to&#x02010;severe plaque psoriasis</article-title>. <source>N Engl J Med</source>
<year>2016</year>; <volume>375</volume>: <fpage>345</fpage>&#x02013;<lpage>356</lpage>.<pub-id pub-id-type="pmid">27299809</pub-id></mixed-citation></ref><ref id="jde13927-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jde13927-cit-0005">
<string-name>
<surname>Griffiths</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Reich</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Comparison of ixekizumab with etanercept or placebo in moderate&#x02010;to&#x02010;severe psoriasis (UNCOVER&#x02010;2 and UNCOVER&#x02010;3): results from two phase 3 randomised trials</article-title>. <source>Lancet</source>
<year>2015</year>; <volume>386</volume>: <fpage>541</fpage>&#x02013;<lpage>551</lpage>.<pub-id pub-id-type="pmid">26072109</pub-id></mixed-citation></ref><ref id="jde13927-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jde13927-cit-0006">
<string-name>
<surname>Saeki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ishii</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic>
<article-title>Efficacy and safety of open&#x02010;label ixekizumab treatment in Japanese patients with moderate&#x02010;to&#x02010;severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis</article-title>. <source>J Eur Acad Dermatol Venereol</source>
<year>2015</year>; <volume>29</volume>: <fpage>1148</fpage>&#x02013;<lpage>1155</lpage>.<pub-id pub-id-type="pmid">25355284</pub-id></mixed-citation></ref><ref id="jde13927-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jde13927-cit-0007">
<string-name>
<surname>Saeki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakajo</surname>
<given-names>K</given-names>
</string-name>
<italic>et al</italic>
<article-title>Efficacy and safety of ixekizumab treatment for Japanese patients with moderate&#x02010;to&#x02010;severe plaque psoriasis, erythrodermic psoriasis, and generalized pustular psoriasis: results from a 52 week, open&#x02010;label, phase 3 study (UNCOVER&#x02010;J)</article-title>. <source>J Dermatol</source>
<year>2017</year>; <volume>44</volume>: <fpage>355</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">27726163</pub-id></mixed-citation></ref><ref id="jde13927-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jde13927-cit-0008">
<string-name>
<surname>Phan</surname>
<given-names>NQ</given-names>
</string-name>, <string-name>
<surname>Blome</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fritz</surname>
<given-names>F</given-names>
</string-name>
<italic>et al</italic>
<article-title>Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus</article-title>. <source>Acta Derm Venereol</source>
<year>2012</year>; <volume>92</volume>: <fpage>502</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">22170091</pub-id></mixed-citation></ref><ref id="jde13927-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jde13927-cit-0009">
<string-name>
<surname>Finlay</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>GK</given-names>
</string-name>. <article-title>Dermatology Life Quality Index (DLQI)&#x02013;a simple practical measure for routine clinical use</article-title>. <source>Clin Exp Dermatol</source>
<year>1994</year>; <volume>19</volume>: <fpage>210</fpage>&#x02013;<lpage>216</lpage>.<pub-id pub-id-type="pmid">8033378</pub-id></mixed-citation></ref><ref id="jde13927-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jde13927-cit-0010">
<string-name>
<surname>Rich</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Scher</surname>
<given-names>RK</given-names>
</string-name>. <article-title>Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis</article-title>. <source>J Am Acad Dermatol</source>
<year>2003</year>; <volume>49</volume>: <fpage>206</fpage>&#x02013;<lpage>212</lpage>.<pub-id pub-id-type="pmid">12894066</pub-id></mixed-citation></ref><ref id="jde13927-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jde13927-cit-0011">
<string-name>
<surname>Asahina</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Etoh</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ohtsuki</surname>
<given-names>M</given-names>
</string-name>. <article-title>Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study</article-title>. <source>J Dermatol</source>
<year>2010</year>; <volume>37</volume>: <fpage>299</fpage>&#x02013;<lpage>310</lpage>.<pub-id pub-id-type="pmid">20507398</pub-id></mixed-citation></ref><ref id="jde13927-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jde13927-cit-0012">
<string-name>
<surname>Igarashi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>H</given-names>
</string-name>. <article-title>Efficacy and safety of ustekinumab in Japanese patients with moderate&#x02010;to&#x02010;severe plaque&#x02010;type psoriasis: long&#x02010;term results from a phase 2/3 clinical trial</article-title>. <source>J Dermatol</source>
<year>2012</year>; <volume>39</volume>: <fpage>242</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">21955098</pub-id></mixed-citation></ref><ref id="jde13927-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jde13927-cit-0013">
<string-name>
<surname>Ohtsuki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Secukinumab efficacy and safety in Japanese patients with moderate&#x02010;to&#x02010;severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo&#x02010;controlled, phase 3 study</article-title>. <source>J Dermatol</source>
<year>2014</year>; <volume>41</volume>: <fpage>1039</fpage>&#x02013;<lpage>1046</lpage>.<pub-id pub-id-type="pmid">25354738</pub-id></mixed-citation></ref><ref id="jde13927-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jde13927-cit-0014">
<string-name>
<surname>Asahina</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ohtsuki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Etoh</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Adalimumab treatment optimization for psoriasis: results of a long&#x02010;term phase 2/3 Japanese study</article-title>. <source>J Dermatol</source>
<year>2015</year>; <volume>42</volume>: <fpage>104</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">25470215</pub-id></mixed-citation></ref></ref-list></back></article>